Feb 17 (Reuters) - STAAR Surgical Co STAA.O:
FDA EXPANDS U.S. AGE INDICATION FOR EVO ICL AS LONG-TERM SAFETY DATA REINFORCES MARKET SHIFT AWAY FROM LASER VISION CORRECTION
STAAR SURGICAL CO - FDA EXTENDS EVO ICL USE TO PATIENTS 21-60 YEARS OLD
Source text: ID:nBw1pM85Va
Further company coverage: STAA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.